5:07 PM
 | 
Aug 11, 2015
 |  BC Extra  |  Clinical News

Adynxx meets in pain relief Phase II

Adynxx Inc. (San Fransisco, Calif.) said AYX1 significantly reduced pain in a placebo-controlled Phase II trial to reduce acute and chronic pain. AYX1, a small synthetic dsDNA inhibitor of early growth response 1...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >